Trial watch: bispecific antibodies for the treatment of relapsed or refractory large B-cell lymphoma

Trial watch: bispecific antibodies for the treatment of relapsed or refractory large B-cell lymphoma

Immunotherapy has shaped the treatment approach to diffuse large B-cell lymphoma (DLBCL), with rituximab leading to remarkable improvements in outcomes for both relapsed and treatment-naïve patients. Recently, groundbreaking immunotherapies like chimeric antigen receptor T-cells have entered the tre...

Full description

Saved in:
Bibliographic Details
Main Authors: Giulio Cassanello, Alejandro Luna de Abia, Lorenzo Falchi
Format: Article
Language:English
Published: Taylor & Francis Group 2024-12-01
Series:OncoImmunology
Subjects:
Bispecific antibodies
DLBCL
Epcoritamab
Glofitamab
Immunotherapy
Online Access:https://www.tandfonline.com/doi/10.1080/2162402X.2024.2321648
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.tandfonline.com/doi/10.1080/2162402X.2024.2321648

Similar Items